Hutchison China Meditech Ltd (LON:HCM) has been reiterated to Buy in a statement by Beaufort Securities earlier today.
- Updated: September 19, 2016
Yesterday Hutchison China Meditech Ltd (LON:HCM) traded 0.27% lower at 1,862.50GBX. Hutchison China Meditech Ltd’s 50-day moving average is 1,837.64GBX and its 200-day moving average is 1,884.38GBX. With the last stock close down 3.28% from the 200-day average, compared with the S&P 500 Index which has decreased -0.01% over the same period. Trade volume was was up over the average, with 26,711 shares of HCM changing hands over the typical 11,536 shares..
Beaufort Securities has reiterated Hutchison China Meditech Ltd(LON:HCM) to Buy in a report released 8/03/2016.
Also covering Hutchison China Meditech Ltd’s stock price target, a total of 2 brokers have issued a research note on HCM. The 12-month target price is 19.00GBX with 0 rating the company a strong buy, 0 rating the stock a buy, 0 firms rating the stock a hold, 0 rating the stock to underperform, and finally 0 firms rating the stock as sell.
With a market cap of 0.0 GBX, Hutchison China Meditech Ltd has a price-earnings of 0 with a one-year low of 1,612.50GBX and a one-year high of 2,896.60GBX.
Brief Synopsis About Hutchison China Meditech Ltd (LON:HCM)
Hutchison China MediTech Limited (Chi-Med) is a China-based, globally-focused healthcare group. The Company researches, develops, and manufactures and sells pharmaceuticals and health-related consumer products. Its Innovation Platform focuses on discovering and developing therapeutics in oncology and autoimmune diseases for the global market. Its Commercial Platform manufactures markets and distributes prescription drugs and consumer health products in China.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.